+ Quarterly incentive compensation + Equity-based long-term incentive program
Neurocrine Biosciences develops and commercializes medicines for neurological and endocrine diseases. Its work centers on discovering and developing treatments, with INGREZZA (valbenazine) approved to treat adults with tardive dyskinesia and a pipeline of other drug candidates in various clinical stages. The company earns revenue from sales of approved medicines and from milestones and royalties from collaborations with partners. By focusing on both neurological and endocrine conditions, Neurocrine targets patients and healthcare professionals seeking therapies for conditions such as tardive dyskinesia, Parkinson's disease, and endometriosis. Its main goal is to bring therapies to market through development and commercialization, supported by ongoing research across its clinical programs to address unmet medical needs in these areas.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1992
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Parental Leave
Health Insurance
Dental Insurance
Vision Insurance
Paid Holidays
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Neurocrine Biosciences announces initiation of Phase 1 clinical study evaluating NBIP-'1968, a glp-1/gip/glucagon receptor triple agonist. Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity. "Obesity is a complex chronic disease driven by multiple biological pathways, underscoring the need for additional treatment options," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "NBIP-'1968 is designed to engage three complementary metabolic mechanisms, reflecting our commitment to exploring multiple scientific approaches to obesity." The Phase 1 study initially will evaluate the safety and tolerability of single ascending doses of NBIP-'1968 in adult participants across a range of body mass index categories, including overweight and obese. Innovations in treatment by Neurocrine bioscience. NBIP-'1968 is an internally discovered, investigational long-acting triple agonist designed for once-weekly subcutaneous administration. It targets the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon to influence metabolic pathways involved in appetite regulation, energy balance and glycemic control. NBIP-'1968 was designed with balanced glucagon receptor activity to optimize the potential metabolic benefits of glucagon receptor activation while supporting tolerability. Neurocrine is developing NBIP-'1968 as part of a broader obesity portfolio that includes NBIP-'2118, an investigational corticotropin-releasing factor type 2 receptor agonist currently in Phase 1 development. NBIP-'1968 is intended for use in a fixed-dose combination with NBIP-'2118. The company's obesity research also includes earlier-stage programs designed to explore complementary mechanisms and extended dosing intervals. "Advancing NBIP-'1968 into the clinic marks another important step in building our obesity portfolio," said Jude Onyia, Ph.D., Chief Scientific Officer, Neurocrine Biosciences. "Our strategy is to explore complementary and differentiated mechanisms that may improve weight loss, preserve lean mass and ultimately address the diverse needs of people living with obesity." About Obesity Obesity is a chronic disease characterized by excess body fat and is associated with serious health conditions, including type 2 diabetes, cardiovascular disease, obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis/fatty liver disease, certain cancers and osteoarthritis. It is driven by complex biological, environmental, and genetic factors - not simply lifestyle or willpower. Obesity has reached epidemic levels worldwide, affecting a significant proportion of adults and placing a substantial burden on public health systems. Despite recent advances in treatment, there remains a need for additional therapies that support safe, effective and sustainable long-term weight management. Current therapies can have challenges with respect to gastrointestinal tolerability, dose titration, and muscle loss. More news. August 7, 2026 August 6, 2026
Neurocrine Biosciences reported revenue of $959 million for the quarter ended June 2026, marking a 39.5% year-on-year increase. The figure surpassed the consensus estimate of $901.54 million by 6.37%. Earnings per share came in at $2.85, up from $1.06 a year earlier and beating the consensus estimate of $2.26 by 26.11%. Product sales reached $954.3 million, exceeding analyst estimates of $881.08 million. INGREZZA sales totalled $716 million, above the $628.59 million forecast, whilst CRENESSITY generated $184 million against an estimated $170.78 million. Collaboration revenue came in at $4.7 million, below the $6.02 million estimate and down 14.6% year-on-year. Shares rose 7.8% over the past month.
Neurocrine Biosciences releases Q2 2026 financial results. Neurocrine Biosciences, Inc. AlphaStreet Newsdesk powered by AlphaStreet Intelligence NBIX | EPS $2.85 vs $1.94 est (+46.9%) | Rev $959.0M vs $888.2M est (+8.0%) | Net Income $144.4M Neurocrine Biosciences, Inc. delivered a blowout second quarter, crushing Wall Street expectations as the neuroscience-focused company posted non-GAAP earnings per share of $2.85, well above the $1.94 analyst consensus and representing a beat of 46.9% based on estimates from 14 analysts. Revenue of $959.0M exceeded the $888.2M forecast by 8.0%, marking a sharp acceleration in growth for the San Diego-based biopharmaceutical firm. Earnings call transcripts The company's performance reflected surging demand across its portfolio, with revenue climbing 39.0% from $688.0M in the year-ago quarter. Adjusted net income reached $296.7M as Neurocrine continued to expand its footprint in the treatment of neurological and endocrine disorders. The strong quarterly results were powered by INGREZZA, the company's flagship tardive dyskinesia treatment, which generated $716.0M in revenue and grew 15.0% year-over-year, cementing its position as a leading therapy in movement disorders. Looking ahead, Neurocrine set full-year revenue guidance at $2.83B to $2.88B, reflecting confidence in sustained momentum across its commercial portfolio. The company has been capitalizing on expanding indications and market penetration for its approved therapies while advancing its pipeline of novel treatments targeting central nervous system conditions. A detailed analysis of Neurocrine Biosciences, Inc.'s quarter follows shortly on AlphaStreet. This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content. Discover more Company profile database Brokerages & Day Trading Stock research tools
Neurocrine Biosciences reported second-quarter 2026 revenue of $959 million, up 39% year-over-year. The San Diego-based biopharmaceutical company raised its full-year guidance for INGREZZA to $2.825–$2.875 billion, up from $2.7–$2.8 billion. INGREZZA net product sales reached $716 million in the quarter, reflecting 15% growth. CRENESSITY sales totalled $184 million, whilst VYKAT XR contributed $54 million following the May acquisition of Soleno Therapeutics. The company completed its $2.9 billion acquisition of Soleno in May 2026, paying $53 per share in cash. Neurocrine also secured a $1 billion revolving credit facility for general corporate purposes. GAAP net income was $144 million, compared with $108 million in the prior-year period. Non-GAAP net income reached $297 million versus $166 million a year earlier.